Madrid, September 9, 2026

Pursuant to the provisions of Article 228 of Law 6/2023, of March 17, on Securities Markets and Investment Services, and related provisions, as well as Circular 3/2020 on information to be provided by companies listed on the BME Growth segment of BME MTF Equity (the **"BME Growth Circular** 3/2020"), LABIANA HEALTH, S.A. ("LABIANA" or the "Company") hereby provides the following:

OTHER RELEVANT INFORMATION

Regulatory and Commercial Progress in the Human and Animal Health Portfolio

Labiana continues to make progress in executing its growth and internationalization strategy by obtaining new marketing authorizations in Europe and Latin America, as well as through the launch of two veterinary drugs in Spain.

In the human health sector, the Company has obtained the following marketing authorizations:

- Two authorizations in Sweden and two others in Portugal for medications based on empagliflozin, an active ingredient used in the treatment of type 2 diabetes mellitus.
- Two authorizations in the Netherlands for medications based on octreotide, an active ingredient used in the treatment of certain endocrine and digestive disorders.

Furthermore, under a licensing and supply agreement signed with a Latin American pharmaceutical company, Labiana has obtained the first five marketing authorizations for Precyst®, a dietary supplement formulated with D-mannose and cranberry extract and intended for women's health.

This agreement covers the supply and marketing of the product in a total of seven Latin American countries. The marketing authorizations obtained represent a preliminary step toward the gradual launch of the product in the relevant markets.

In the animal health sector, Labiana has recently begun marketing two new injectable veterinary drugs in Spain:

- A robenacoxib-based medication intended for the treatment of pain and inflammation in dogs and cats.
- A medication based on acepromazine, indicated as a sedative and preanesthetic for dogs.

These developments are part of Labiana's strategy to expand its proprietary portfolio, develop its regulatory and industrial capabilities, and strengthen the international marketing of its human and animal health products.

As of the date of this announcement, the Company does not have sufficient information to accurately quantify the future economic impact resulting from these authorizations and launches. Such impact will depend, among other factors, on the actual marketing timeline, the evolution of demand, and sales performance in each market.

In accordance with the provisions of BME Growth Circular 3/2020, it is noted that the information disclosed has been prepared under the sole responsibility of the Company and its directors.

Mr. Manuel Ramos Ortega,
Chairman and Chief Executive
Officer of LABIANA HEALTH, S.A.